FDA-Approved Molecular Imaging and Therapeutic Radiopharmaceuticals from 2011 to 2021 (6,7)
| Year of approval | Drug | Indication | Modality |
|---|---|---|---|
| 2011 | 123I-ioflupane (DaTscan; GE Healthcare) | Parkinson disease | Single-photon imaging |
| 2012 | 18F-florbetapir (Amyvid; Eli Lilly) | Alzheimer disease | PET brain imaging |
| 2012 | 11C-choline (Mayo Clinic) | Prostate CANCER | PET oncology |
| 2013 | 123I-MIBG iobenguane (Progenics) | Pheochromocytoma, paraganglioma | Single-photon imaging |
| 2013 | 223Ra-dichloride (Xofigo; Bayer Healthcare) | Prostate cancer | Radiopharmaceutical therapy |
| 2013 | 18F-flutemetamol (Vizamyl; GE Healthcare) | Alzheimer disease | PET brain imaging |
| 2014 | 18F-florbetaben (Neuraceq; Piramal) | Alzheimer disease | PET brain imaging |
| 2016 | 18F-fluciclovine (Axumin; Blue Earth) | Prostate cancer | PET oncology |
| 2016 | 68Ga-DOTATATE (Netspot; AAA/Novartis) | Neuroendocrine cancer | PET oncology |
| 2018 | 177Lu-DOTATATE (Lutathera; AAA/Novartis) | Neuroendocrine cancer | Radiopharmaceutical therapy |
| 2018 | 131I-MIBG iobenguane (Azedra; Progenics) | Pheochromocytoma, paraganglioma | Radiopharmaceutical therapy |
| 2019 | 68Ga-DOTATOC (University of Iowa) | Neuroendocrine cancer | PET oncology |
| 2019 | 18F-fluorodopa (Feinstein Institute) | Parkinson disease | PET brain imaging |
| 2020 | 18F-fluoroestradiol (Cerianna; Zionexa) | Breast cancer | PET oncology |
| 2020 | 18F-flortaucipir (Tauvid; Lilly) | Alzheimer disease | PET brain imaging |
| 2020 | 64Cu-DOTATATE (Detectnet; RadioMedix-Curium) | Neuroendocrine cancer | PET oncology |
| 2020 | 68Ga PSMA-11 (UCSF–UCLA) | Prostate cancer | PET oncology |
| 2021 | 18F-DCFPyL or 18F-piflufolastat (Pylarify; Lantheus) | Prostate cancer | PET oncology |